Research

Hormonal

Daily administration of GTx-024 (enobosarm) at 3 mg significantly reduces insulin resistance and fasting glucose levels in healthy elderly men and postmenopausal women.

For healthy older adults, a daily 3mg dose of GTx-024 (enobosarm) taken for 12 weeks significantly reduces insulin resistance and fasting glucose levels. This metabolic benefit is comparable to standard diabetes medications like metformin, suggesting potential utility for metabolic health in aging populations.

GoodSupportsHIGH confidence
GTx-024 3 mg significantly (P=0.006) decreased blood glucose an average of 6.9±2.5 (milligrams per deciliter)... insulin resistance (calculated based on the HOMA-IR [29]) was reduced in the GTx-024 1-mg and 3-mg treatment groups (placebo=2.6%±8.6, 1 mg=−9.3%±5.5, 3 mg=−27.5%±7.6: P=0.013 3 mg vs. placebo).
James T. Dalton et al. · Journal of Cachexia Sarcopenia and Muscle · 2011

Why this rating

Phase II, randomized, double-blind, placebo-controlled clinical trial with clear statistical significance.

Source

The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial

James T. Dalton et al. · Journal of Cachexia Sarcopenia and Muscle · 2011

DOI 10.1007/s13539-011-0034-6

rct · n=120Cited 390×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →